Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Nanospectra Biosciences, a US-based thermal ablation technology spinout of Rice University, has raised an undisclosed amount of series B-1 funding led by liver cancer therapy producer Sirtex Medical. Nanospectra is currently conducting multi-centre clinical trials of a nanoparticle near-infrared laser therapy for prostate cancer intended to prevent side-effects associated with existing treatments. The funding will…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.